KOSDAQBiotech & Pharma046210

HLB Panagene

₩1,005▼ 0.20%2026-11-18 close
Market Cap
₩45.8B
Turnover
₩56,637,300
Volume
60K
Shares out.
45.5M
PER
—
PBR
0.7×
EPS
-₩91
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Narrowing losses as PNA materials and AOC expand

HLB Panagene has booked operating losses for five straight quarters through the third quarter of 2026, but the losses have narrowed, and PNA material supply and AOC drug development are the next items to track.

  1. 1

    On a DART-filed basis, 2025 revenue of KRW 15 billion rose for a second straight year, but the operating loss of KRW 3.44 billion marked a third straight year in the red.

  2. 2

    The operating loss narrowed to KRW 141 million in the third quarter of 2026, a smaller deficit than a year earlier, within a run of five straight loss-making quarters.

  3. 3

    Net income attributable to controlling shareholders turned positive at KRW 1.55 billion in the second quarter of 2026 before a KRW 989 million loss in the third quarter; the last four quarters total a KRW 4.1 billion loss.

  4. 4

    The business rests on three pillars: expanding PNA material supply, obtaining European IVDR certification for diagnostic kits, and developing PNA-based AOC drugs.

  5. 5

    Jin Yang-gon, chairman of the HLB group, bought about 300,000 HLB Panagene shares on the open market in February 2026, according to electronic disclosure records.

02

Business structure

HLB Panagene was founded in 2001, merged with Koram Panagene in 2008, and listed on KOSDAQ; it is now an affiliate of the HLB group. Its core businesses are molecular diagnostics based on its PNA (peptide nucleic acid) platform and immunodiagnostics based on quantum-pack technology.

In molecular diagnostics, it has commercialized a somatic mutation detection platform used as a companion diagnostic for cancer targeted therapies and is extending it into liquid biopsy.

PNA is a synthetic molecule in which the DNA or RNA backbone is replaced with a peptide structure, and the company says it is highly stable because nuclease enzymes do not act on it.

The company is presented as holding PNA mass-production patents and exclusive supply rights, and expanded PNA material supply was cited as a factor behind the profitable first half of 2026.

Overseas, it obtained approvals in Saudi Arabia and the UAE and has built sales there through partnerships over several years, and it plans to use that distribution base to expand into neighboring GCC countries and Europe.

In January 2026 it secured exclusive domestic distribution rights for RocGene Technology's point-of-care testing (POCT) products, widening its supply channels to research institutes and hospitals.

Its subsidiary's quantum-dot immunodiagnostics business and its spatial proteomics analysis technology also broaden the diagnostics franchise. On the drug side, it is developing PNA-based antibody-oligonucleotide conjugate (AOC) candidates with partners and has set DMD as the first indication.

Revenue contribution comes mainly from diagnostic kits and PNA material supply, while new drugs remain at an early stage.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.6B-₩800M−22.8%
2025Q4₩4.2B-₩1.7B−39.6%
2026Q1₩3.1B-₩700M−23.9%
2026Q2₩3.7B-₩200M−4.3%
2026Q3₩3.5B-₩100M−4.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩14.2B₩1.6B₩2.2B11.1%7.1%9.4%
2023₩12.3B-₩1.8B-₩4.8B−15.0%−7.6%43.0%
2024₩13.2B-₩1.4B-₩1.9B−10.3%−2.6%44.0%
2025₩15B-₩3.4B-₩3.1B−22.9%−4.3%28.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-11

04

Earnings analysis

On a DART-filed basis, annual revenue fell from KRW 14.2 billion in 2022 to KRW 12.3 billion in 2023, a 13.5% decline, then rose to KRW 13.2 billion in 2024 and KRW 15 billion in 2025, a second straight year of growth; 2025 is the largest year in the 2022–2025 period.

Operating profit of KRW 1.58 billion in 2022 turned into an operating loss of KRW 1.84 billion in 2023, and the company has posted operating losses for three straight years, with KRW 1.36 billion in 2024 and KRW 3.44 billion in 2025.

For the wider 2025 loss, the company pointed to higher investment costs for new business expansion and higher ordinary R&D expenses, and disclosed that an impairment of goodwill at a subsidiary increased the net loss.

The operating margin moved from 11.1% in 2022 to -15.0% in 2023, -10.3% in 2024 and -22.9% in 2025, so it has not yet returned to profitability.

Net income attributable to controlling shareholders went from KRW 2.24 billion in 2022 to a KRW 4.82 billion loss in 2023, a KRW 1.94 billion loss in 2024 and a KRW 3.13 billion loss in 2025; total net income including non-controlling interests, a KRW 2.09 billion loss in 2024, is a different figure.

Operating cash flow fell from KRW 3.36 billion in 2022 to -KRW 641 million in 2025, a sign of weaker cash generation. At year-end 2025, total liabilities were KRW 20.5 billion and total equity KRW 72.4 billion, and the debt ratio of 28.3% was lower than the 40%-plus levels of 2023 and 2024.

Quarterly revenue went from KRW 3.64 billion in the third quarter of 2025 and KRW 4.23 billion in the fourth quarter to KRW 3.13 billion in the first quarter of 2026, then KRW 3.71 billion and KRW 3.54 billion in the second and third quarters, with the third quarter down 2.6% year on year.

The operating loss peaked at KRW 1.68 billion in the fourth quarter of 2025 and narrowed to KRW 749 million, KRW 158 million and KRW 141 million over the first three quarters of 2026, which extends five straight loss-making quarters but with a smaller deficit.

Net income attributable to controlling shareholders swung to a KRW 1.55 billion profit in the second quarter of 2026 after a KRW 3.59 billion loss in the fourth quarter of 2025, then returned to a KRW 989 million loss in the third quarter, and the last four quarters total a KRW 4.1 billion loss.

The first-half figures the company announced on August 14, 2026 (separate basis: revenue KRW 6.82 billion, operating profit KRW 526 million) use a different basis from the consolidated DART figures and are not added to them.

05

Industry analysis

The end market the company emphasizes is nucleic acid therapeutics. According to The Insight Partners, the global nucleic acid therapeutics market is projected to grow from about USD 8.03 billion in 2025 to about USD 25.85 billion in 2034, a compound annual growth rate of 15.74%.

That is an outside estimate and does not translate directly into the company's revenue growth. The company argues that PNA materials gain uses as more therapies directly target genes or RNA.

On the drug side, it plans to prove PNA's superiority in a market already established by PMO-based drugs before expanding into hereditary rare diseases.

AOCs attach oligonucleotides to antibodies to deliver them to chosen tissues or cells, and the approach is drawing attention as a next-generation precision delivery platform after ADCs. Analysts also say the market is shifting toward evaluating the parent, HLB, on a mix of operating results and new-drug momentum.

In diagnostics, IVDR certification under the EU's in-vitro diagnostic regulation has become a prerequisite for EU market entry, so certification speed translates into competitiveness. Edaily framed this certification race in Europe as a contest with Chinese competitors. In PNA materials, the company's claim to exclusive supply rights is its main point of differentiation.

06

Outlook

For the second half, the company named stronger domestic and overseas sales of PNA materials, faster AOC development, and more visible results. For AOC, it started development with a partner, setting DMD as the first indication, and it has said it is aiming for a technology export in 2028.

In diagnostics, it has completed IVDR certification for sexually transmitted infection (STI) and cervical cancer (HPV) kits and plans to certify the full cancer diagnostics range within 2026.

Cancer diagnostic kits have just over two years before the regulatory deadline, but the company aims to finish certification this year. Overseas, sales are already being generated in Saudi Arabia and the UAE, and the company plans to expand into GCC countries such as Oman, Qatar and Kuwait, and into Europe.

Exclusive domestic distribution of RocGene's POCT products is a way to widen supply to research institutes, hospitals and clinical labs. The CEO said the company is working with hospitals to use spatial proteomics analysis on archived tissue slides to find biomarkers.

The company has not set quantitative targets, and from its filings, PNA material sales are the key variable for an earnings recovery. The chairman's open-market purchases in February 2026 were, according to the group, a reflection of expectations for the medium-to-long-term growth potential of the AOC platform.

07

Valuation

PER
—
PBR
0.7×
ROE
-5.5%
EPS
-₩91
BPS
₩1,553
Dividend per share
₩0

Because the last four quarters have produced a combined loss attributable to controlling shareholders, a P/E ratio cannot be calculated. The price-to-book ratio is below 1x, so the stock trades below book net assets.

Compared with total equity of KRW 72.4 billion at year-end 2025, the market value sits below book equity, which is a factual comparison of price against assets. The dividend yield is effectively nil.

Reading this relationship depends on whether the operating margin can return to the profitable territory of 2022, when it was 11.1%, from -22.9% in 2025. Related parties led by HLB hold 20.82%, which shapes the structure of the shares that trade in the market.

The chairman's open-market purchases are a confirmed fact, and the company said they reflect expectations for medium-to-long-term growth.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-11

08

Bull factors

PNA material supply and profit track record

The company announced a separate-basis operating profit for the first half of 2026 and said the profit streak continues from 2024 and 2025. Expanded PNA material supply, cited as the reason, is tied to growth in nucleic acid therapeutics. It has also signed new contracts based on its own PNA technology and production capacity.

Diagnostic certifications and overseas approvals

Its STI and HPV diagnostic kits have completed IVDR certification, and it targets certifying the cancer diagnostic range within 2026. Sales are already generated in Saudi Arabia and the UAE, and the company plans to extend that base to GCC neighbors and Europe. Exclusive domestic distribution of RocGene's POCT products also widens its diagnostics channel.

AOC pipeline and a technology export target

PNA-based AOC candidates are in development with a partner, with DMD set as the first indication. The company has set a 2028 technology export as its target, and if the drug platform produces results it could change the business mix beyond diagnostics. The chairman's open-market purchases in February 2026 are a factual signal of interest in the AOC platform.

09

Bear factors

Three straight years of operating losses

The 2025 operating loss of KRW 3.44 billion was larger than the KRW 1.36 billion loss in 2024, with an operating margin of -22.9%. The company cited investment costs, higher R&D spending and a subsidiary's goodwill impairment. Operating cash flow also turned to -KRW 641 million in 2025.

Uncertainty in the revenue recovery

Third-quarter 2026 revenue of KRW 3.54 billion fell 2.6% from a year earlier. A securities data service showed first-half 2026 consolidated revenue down 4.7% and net income down 24.2%. Quarterly revenue has not risen steadily through 2026.

Profit direction shifts from quarter to quarter

In the second quarter of 2026, net income attributable to controlling shareholders was a KRW 1.55 billion profit despite a KRW 158 million operating loss, but in the third quarter it swung to a KRW 989 million loss.

Despite the second-quarter profit, the four quarters combined still show a net loss attributable to controlling shareholders. Non-operating items appear to drive the direction of net income.

10

Risk factors

Regulatory and certification risk

IVDR certification is a prerequisite for EU market entry, so any delay in certifying the cancer diagnostic range would slow European expansion. Cancer kits have just over two years before the regulatory deadline, but schedule slippage would affect overseas plans. Competitors' certification pace is also a variable.

Early-stage pipeline risk

The AOC candidates are at the start of development with a partner, targeting DMD as the first indication. The 2028 technology export is a company target, and clinical results and partner terms are not yet settled. If drug results are delayed, the diagnostics and materials businesses must carry the losses for longer.

Subsidiary impairment and ownership concentration

Goodwill impairment at a subsidiary was one cause of the wider 2025 net loss, and weaker subsidiary results could bring further impairments into consolidated earnings. Related parties hold 20.82%, which leaves a limited free float, so price moves may be sensitive to trading volume.

11

What to watch next

  1. By December 2026 (year-end target)

    Whether the cancer diagnostic range receives IVDR certification, which the company set as a year-end target; completion would widen European supply.

  2. Late December 2026

    New PNA material contracts and AOC development progress, which the company named as second-half milestones; how much material sales show up in quarterly results is the test.

  3. Around February 2027

    Preliminary 2026 annual results; last year's annual figures were disclosed on February 12, 2026, and the focus is the fourth-quarter operating and net loss.

  4. Late March 2027 (annual report filing deadline)

    The 2026 annual report, the next regular filing, which will confirm full-year 2026 revenue, operating margin and net loss attributable to controlling shareholders.

  5. Mid-May 2027 (quarterly report filing deadline)

    First-quarter 2027 results, showing whether the narrowing losses continue and how non-operating items move.

12

Overall view

On a DART-filed basis, HLB Panagene's 2025 revenue rose for a second straight year to KRW 15 billion, but its KRW 3.44 billion operating loss marked a third straight year in the red.

Quarterly operating losses narrowed to KRW 141 million by the third quarter of 2026, and net income attributable to controlling shareholders turned positive in the second quarter.

However, third-quarter revenue declined year on year, and the last four quarters total a KRW 4.1 billion loss attributable to controlling shareholders. Bullish factors are the narrowing losses, expanding PNA material supply and an overseas approval base centered on Saudi Arabia and the UAE.

Bearish factors are the continued annual losses, weaker operating cash flow and uncertainty in the revenue recovery. The AOC drug pipeline has a company target of a 2028 technology export, but it remains early, so the timing of results is open.

The next checkpoints are the year-end 2026 IVDR result for cancer diagnostics, preliminary 2026 annual results in early 2027, and the size of the annual operating loss in the 2026 annual report due by late March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.wisereport.co.kr
  2. greened.kr
  3. m.news.nate.com
  4. news.nate.com
  5. m.news.nate.com
  6. m.news.nate.com
  7. newspim.com
  8. news.mtn.co.kr
  9. panagene.com
  10. medigatenews.com
  11. news.nate.com
  12. m.news.nate.com
  13. job-post.co.kr
  14. comp.wisereport.co.kr
  15. hankyung.com
  16. judal.co.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis